Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study

被引：0
|
作者：
Cook, S.
Vermersch, P.
Comi, G.
Giovannoni, G.
Rammohan, K.
Rieckmann, P.
Sorensen, P. S.
Chang, P.
Hamlett, A.
Musch, B.
Viglietta, V.
Greenberg, S.
机构：
[1] Univ Med & Dent, Newark, NJ USA
[2] Univ Lille, Lille, France
[3] Univ Vita Salute, Milan, Italy
[4] Barts & London Queen Marys Sch Med & Dent, London, England
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] Rigshosp, DK-2100 Copenhagen, Denmark
[8] Merck Serono SA, Geneva, Switzerland
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [21] Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study
    Rammohan, K.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Kurukulasuriya, N.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 21 - 21
  • [22] Effects of Cladribine Tablets on Circulating Lymphocyte Subset Reconstitution in the 96-Week CLARITY Study in Relapsing-Remitting Multiple Sclerosis (RRMS)
    Soelberg, Per
    Rieckmann, Peter
    comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rammohan, Kottil
    Vermersch, Patrick
    Bock, Daena
    Hamlett, Anthony
    Fevr, Tea
    Musch, Bruno
    Greenberg, Steve
    NEUROLOGY, 2010, 74 (09) : A372 - A372
  • [23] Reconstitution of circulating lymphocyte subsets after treatment with cladribine tablets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis
    Sorensen, P. Soelberg
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Vermersch, P.
    Bock, D.
    Hamlett, A.
    Fevr, T.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S143 - S143
  • [24] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Fevr, T.
    Musch, B.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 215 - 215
  • [25] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Verjee, R.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S21 - S21
  • [26] Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets, in the Double-Blind, 96-Week CLARITY Study
    Giovannoni, Gavin
    Cami, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Chang, Peter
    Hamlett, Anthony
    Veriee, Rehan
    Musch, Bruno
    Greenberg, Steven
    NEUROLOGY, 2010, 74 (09) : A295 - A296
  • [27] Consistent efficacy of cladribine tablets across multiple sclerosis and patient characteristics, in the double-blind, 96-week CLARITY study
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Sorensen, P. Soelberg
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Verjee, R.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S142 - S143
  • [28] Consistent Efficacy of Cladribine Tablets across Multiple Sclerosis and Patient Characteristics, in the Double-Blind, 96-Week CLARITY Study
    Rammohan, Kottil
    Comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Chang, Peter
    Hamlett, Anthony
    Verjee, Rehan
    Musch, Bruno
    Greenberg, Steven
    NEUROLOGY, 2010, 74 (09) : A166 - A167
  • [29] Effects of Cladribine Tablets in Lymphocyte Subtypes: Insights from the Phase III, 96-Week, Double-Blind CLARITY Study
    Farmer, Pierre
    Guilleret, Isabelle
    Di Cara, Alessandro
    Lamarine, Marc
    Salvat, Catherine
    Weissert, Robert
    Monnet, Emmanuel
    NEUROLOGY, 2011, 76 (09) : A240 - A240
  • [30] Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Sorensen, P. S.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Viglietta, V.
    Musch, B.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S248 - S249
12345